Somnus Therapeutics (Bedminster, NJ) a clinical-stage specialty pharmaceutical company focused on a delayed-release sleep-maintenance therapy, closed a $15M Series A financing. Participants include CTI Life Sciences Fund and Care Capital.

TransOral Pharmaceuticals (Point Richmond, CA) a specialty pharmaceutical company CNS platform targeting insomnia and alcohol dependence, closed a $40M Series D financing. The deal was led by New Enterprise Associates additional participants included New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton BioVentures, Vivo Ventures and Peninsula Equity Partners.